Webinar: “Discover the full complexity of cellular diversity, cell by cell with CeGaT and 10x Genomics”

/in /by

Join us for our upcoming webinar with 10x Genomics titled “Discover the full complexity of cellular diversity, cell by cell with CeGaT and 10x Genomics”. Accelerate your research with single-cell solutions!

In three presentations, you will learn:

  • about the technical aspects of performing 3´scRNA seq with CeGaT
  • how 10x Genomics solutions guide you through the workflow from sample preparation to sequencing to subsequent analysis and visualization
  • about a real-world example case where single-cell sequencing contributes to the understanding of mitochondrial dysfunction in Parkinson’s disease

Mark your calendars for the webinar on Tuesday, April 18, from 10.00 a.m. – 11.30 a.m. (CET) and take advantage of the opportunity to revolutionize your research.

Register Now

Our Service for Your Clinical Study: Benefit from CeGaT’s Many Years of Experience

/in , /by

Our service provides you with our expertise in next-generation sequencing (NGS). You will receive support in all steps of your clinical study to achieve the best possible results within the shortest time.

NGS is the basis of precision medicine and provides the most comprehensive data to answer your clinical questions. NGS helps to better understand diseases and to develop drugs in a targeted manner. With many years of experience, we are aware of the challenges associated with analyzing clinical samples and can be flexible to meet your needs. We support university hospitals and companies from the biotech and pharmaceutical industries with, e.g., genome, exome, and transcriptome sequencing, as well as analyses from liquid biopsies or HLA typing. Together we determine the optimal choice of NGS services for your clinical trial and assist you in the following:

  • trial design,
  • preparation of study-relevant documents,
  • communication with study centers,
  • long-term data storage and
  • storage of samples.

Throughout the whole project, you will be supported by a dedicated expert. For the collection of clinical samples, we provide you with customized sampling kits. In addition, our experienced logistics team will be happy to advise you on sample shipment and take care of the entire organization.

All steps of the process are performed in-house. Accredited workflows (DIN EN ISO 15189, DIN EN ISO/IEC 17025, CAP, CLIA) guarantee reliable results.

Benefit from a direct exchange to plan and adapt your project, set quality standards, and evaluate the results.

To start your clinical study contact us now at rps@cegat.com.
You can find an overview of our clinical study service here:

To our Clinical Study Service

Illumina NovaSeq™ X Plus: CeGaT is One of the First Companies to Order Illumina’s Brand New Sequencer

/in , , /by

CeGaT is expanding its NGS laboratory with the brand new NovaSeq™ X Plus from Illumina. This strategically important step enables CeGaT to serve the growing global demand for sequencing services and molecular genetic analysis and to make Illumina’s latest sequencing platform available to its customers.

On Monday, October 3rd, 2022, Illumina unveiled its latest advancement – the new series of sequencers, NovaSeq™ X Plus. This platform, coupled with state-of-the-art sequencing chemistry, enables a new dimension of samples to be sequenced in parallel. “We are looking forward to the new challenge and will provide our customers with the well-established quality on the NovaSeq™ X Plus. We will make diagnostic standards available to all researchers and physicians on this sequencer as well,” says Dr. Jiri Ködding, Director Operations.

“We are delighted that CeGaT has chosen to invest in its future with the NovaSeq™ X Plus series to meet its increasing demand for sequencing and genetic analyses,” said Paula Dowdy, Senior Vice President and General Manager of Illumina for Europe, the Middle East, and Africa. “We are reinventing the industry once again with a technology that increases the speed, scale, and accuracy of sequencing that furthers our understanding of genetic diseases to improve human health.”

In addition to the new NovaSeq™ X Plus, CeGaT will continue to use the existing NovaSeq™ 6000 sequencers. This will significantly increase the total sequencing capacity of the owner-operated company in Tübingen. All analyses will be still performed in-house.

Ongoing investment in state-of-the-art technologies

CeGaT invests in state-of-the-art equipment and is constantly expanding its product portfolio for international customers. Rapid turnaround times and the processing of large sample volumes are made possible in this way. Just in April 2022, CeGaT acquired a sixth NovaSeq™ 6000. With the six existing NovaSeq™ 6000s, CeGaT can generate data volumes of up to 36 terabases in less than two days. This sequencing capacity is now significantly expanded by the NovaSeq™ X Plus.

CeGaTs Sequencing Services

New CancerPrecision® Report including a Graphical Representation of Results and Detailed Information on Applicable Drugs

/in , , /by

CeGaT’s new tumor report has been completely revised and raised to an even higher level. Using comprehensive molecular genetic analysis, our report provides doctors and patients with an overview of the medically significant characteristics of their tumor sample. All relevant information, as well as applicable drugs, has been listed in an easy-to-understand format. Thus, you receive all the information you need to initiate the optimal therapy for your patients.

Your advantages of the new CancerPrecision® report:

  • A graphically prepared summary of all medically relevant results on the first page
  • A detailed list of relevant drugs that have been approved for and are specific to your patient’s tumor
  • A detailed list of relevant drugs that have been approved for other tumor entities based on relevant biomarkers identified in the tumor sample
  • A list of all approval conditions & EMA/FDA information for all relevant drugs
  • Detection of all genetic variants that may cause drug resistance
  • A list of pharmacogenetically relevant germline polymorphisms, which may affect drug dosage considerations
  • A new graphical overview of copy number variants (CNV) and relevant signaling pathways
  • Detection of mosaic variants: new biomarker CHIP (Clonal Hematopoiesis of Indeterminate Potential)
  • A table including detected CHIP and PGX variants

Our goal is to provide the most comprehensive and useful diagnostics to you in a timely manner. Our tumor report provides you with all the most medically relevant information to help you decide on the optimal therapy approaches to take.

By choosing CancerPrecision® analysis, you will receive a high level of professionalism and will benefit from the expert knowledge of our interdisciplinary diagnostics team. We will provide you with:

  • Targeted therapy options based on the individual molecular genetic profile of the tumor sample
  • Focused, clear, and meaningful information, which can be used in a clinical review setting, such as the molecular tumor board (MTBs)

We carry out every step from sample receipt to the preparation of the tumor report in-house to ensure that our high-quality requirements are met. We work according to the dual control principle and are accredited as a human genetic diagnostics laboratory according to DIN EN ISO 15189 and the American regulations (CAP/CLIA).

Learn more about our in-house tumor diagnostics here and benefit together with your patients from our comprehensive somatic diagnostics.

Our team is here to support you! We look forward to your questions and will be happy to advise you. Write to us at diagnostic-support@cegat.de.

Our new CancerPrecision® Medical Report


New Exome Diagnostics: ExomeFocus® – Cost-Effective and Fast Results

/in , /by

CeGaT has adapted its in-house exome diagnostics and revised them according to the latest clinical findings. Our ExomeXtra® covers not only all coding regions but, in the third version, also all >22,000 non-coding variants classified as pathogenic or probable pathogenic in the HGMD database. With the new ExomeFocus®, we offer a fast, comprehensive, and inexpensive exome diagnostic that can be used well in an inpatient setting.

We see a high clinical need also for inpatients (pediatrics, neonatology, metabolic centers) to have access to a rapid diagnosis (<12 days) when a genetic disease is suspected. Two years ago, we were able to open up a new dimension in exome diagnostics thanks to our in-house exome enrichment, our optimized bioinformatics software, and our highly skilled diagnostic evaluation experts. With CeGaT ExomeXtra®, your patients benefit from a unique approach that combines the advantages of Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) while circumventing their weaknesses. In doing so, CeGaT ExomeXtra® achieves better results than commercially available WES and WGS and dramatically increases diagnostic yield.

Update: CeGaT ExomeXtra® – newly added variants and optimized coverage enable a further increase in sensitivity

The third version of CeGaT ExomeXtra® includes all variants currently classified as pathogenic or likely pathogenic, with over 22,000 non-coding variants of HGMD and nearly 15,000 variants listed in ClinVar. In addition, we improved the uniformity of coverage further in the design process, thus increasing clinical sensitivity.

This makes CeGaT ExomeXtra® the most effective genetic test for patients with complex, non-specific, and rare diseases. Our proprietary exome enrichment covers not only all protein-coding regions but also all known pathogenic intronic and intergenic variants, providing the most comprehensive database for the most informed genetic diagnosis.

Click here for further information on CeGaT ExomeXtra®.

New: CeGaT ExomeFocus® – focused analysis for cost-efficient results

Based on prioritized high-impact variants, CeGaT’s ExomeFocus® identifies likely pathogenic and pathogenic variants (ACMG classes 4 and 5) in the shortest possible time. This focused analysis enables you to obtain cost-effective results in as little as two to three weeks and less than 12 days in very urgent cases. ExomeFocus® can also be used in a modular fashion or expanded to a trio exome analysis at any time.

Your advantages at a glance:

  • Precise, cost-efficient, and rapid results within 2-3 weeks
  • Expandable at any time
  • Optional ACMG interpretation, PGX reporting, HLA typing possible

More information about CeGaT ExomeFocus® can be found here.

Benefit from our unique approach to exome sequencing and increase the diagnostic yield for your patients.

We look forward to answering your questions and advising you. Please get in touch with us at diagnostic@cegat.com.

Find Out More!